Learn how cilta-cel improved survival, disease control, and symptom outcomes versus standard care in lenalidomide-refractory multiple myeloma.
Read More
Learn how cilta-cel improved survival, disease control, and symptom outcomes versus standard care in lenalidomide-refractory multiple myeloma.
Read MoreExplore recent multiple myeloma research on earlier cilta-cel use, urgent inpatient therapy, racial disparities, and remote healthcare after transplant.
Read MoreLearn how T-cell fitness affects CAR T therapy in multiple myeloma and why earlier treatment with ciltacabtagene autoleucel may improve outcomes.
Read MoreReprinted with permission. Support Care Cancer. 2025;33(5):374.* by Karen Sweiss,* Ana Maria Avila Rodriguez,* John G. Quigley, Lisa Sharp, Kaily Kurzweil, Jaleel G. Sweis, Gregory S. Calip, Zacharie Hamilton, Chukwuemeka Uzoka, Elizabeth Ilo, Elliot Wolf, Damiano Rondelli, Douglas W. Sborov, Pritesh Patel,† and Craig C....
Read MoreLearn how ciltacabtagene autoleucel compared with standard treatments for relapsed/refractory multiple myeloma in this matching-adjusted indirect comparison.
Read MoreExplore key updates from the 2025 International Myeloma Society Meeting, including CAR-T therapy, nursing education, and supportive care advances.
Read More©2026 Oncology Matrix. All Rights Reserved.
